Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Changhoon Yoo

Showing results (61-70 of 250) with videos related to

Pageof 25
Sort By:
Cancers|February 15, 2022
Efficacy of Immune Checkpoint Inhibitors against Advanced or Metastatic Neuroendocrine Neoplasms: A Systematic Review and Meta-AnalysisEun-Joo Park, Hyo-Jung Park, Kyung-Won Kim, et al.
Gastrointestinal Endoscopy|June 27, 2009
Verrucous carcinoma of the esophagusShin Na, Kee Don Choi, Changhoon Yoo, et al.
Annals of Hematology|December 25, 2010
Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOPChanghoon Yoo, Dae Ho Lee, Jeong Eun Kim, et al.
Future Oncology (London, England)|January 12, 2024
Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumorsChanghoon Yoo, Angela Lamarca, Hye Jin Choi, et al.
Journal of Hepatology|April 3, 2024
Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatmentStephen L Chan, Baek-Yeol Ryoo, Frankie Mo, et al.
Investigational New Drugs|September 17, 2013
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamideChanghoon Yoo, Jeeyun Lee, Sun Young Rha, et al.
The American Journal of Surgical Pathology|August 1, 2020
Chromogranin A Expression in Rectal Neuroendocrine Tumors Is Associated With More Aggressive Clinical Behavior and a Poorer PrognosisJisup Kim, Joo Young Kim, Eun Hye Oh, et al.
Frontiers in Oncology|April 6, 2026
Prognostic implications of body composition changes in patients with non-metastatic pancreatic adenocarcinoma treated with mFOLFIRINOXJong Hyuk Lee, Yousun Ko, Seongwon Na, et al.
Journal of Breast Cancer|July 19, 2012
Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in patients with breast cancer following neoadjuvant chemotherapyChanghoon Yoo, Jin-Hee Ahn, Kyung Hae Jung, et al.
EJNMMI Research|June 17, 2020
Tumour-to-liver ratio determined by [<sup>68</sup>Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumoursYong-Il Kim, Changhoon Yoo, Seung Jun Oh, et al.
Pageof 25

Showing results (61-70 of 250) with videos related to

Sort By:
Pageof 25
Cancers|February 15, 2022
Efficacy of Immune Checkpoint Inhibitors against Advanced or Metastatic Neuroendocrine Neoplasms: A Systematic Review and Meta-AnalysisEun-Joo Park, Hyo-Jung Park, Kyung-Won Kim, et al.
Gastrointestinal Endoscopy|June 27, 2009
Verrucous carcinoma of the esophagusShin Na, Kee Don Choi, Changhoon Yoo, et al.
Annals of Hematology|December 25, 2010
Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOPChanghoon Yoo, Dae Ho Lee, Jeong Eun Kim, et al.
Future Oncology (London, England)|January 12, 2024
Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumorsChanghoon Yoo, Angela Lamarca, Hye Jin Choi, et al.
Journal of Hepatology|April 3, 2024
Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatmentStephen L Chan, Baek-Yeol Ryoo, Frankie Mo, et al.
Investigational New Drugs|September 17, 2013
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamideChanghoon Yoo, Jeeyun Lee, Sun Young Rha, et al.
The American Journal of Surgical Pathology|August 1, 2020
Chromogranin A Expression in Rectal Neuroendocrine Tumors Is Associated With More Aggressive Clinical Behavior and a Poorer PrognosisJisup Kim, Joo Young Kim, Eun Hye Oh, et al.
Frontiers in Oncology|April 6, 2026
Prognostic implications of body composition changes in patients with non-metastatic pancreatic adenocarcinoma treated with mFOLFIRINOXJong Hyuk Lee, Yousun Ko, Seongwon Na, et al.
Journal of Breast Cancer|July 19, 2012
Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in patients with breast cancer following neoadjuvant chemotherapyChanghoon Yoo, Jin-Hee Ahn, Kyung Hae Jung, et al.
EJNMMI Research|June 17, 2020
Tumour-to-liver ratio determined by [<sup>68</sup>Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumoursYong-Il Kim, Changhoon Yoo, Seung Jun Oh, et al.
Pageof 25